Brookline Capital Maintains Buy on C4 Therapeutics, Raises Price Target to $30
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Brookline Capital analyst Leah Rush maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and raises the price target from $20 to $30.
Brookline Capital analyst Leah Rush maintains C4 Therapeutics (NASDAQ:CCCC) with a Buy and raises the price target from $20 to $30.